Vical (VICL) Given Daily News Impact Rating of 0.34

Media coverage about Vical (NASDAQ:VICL) has been trending positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vical earned a news impact score of 0.34 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.1727760619193 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

VICL has been the subject of several research analyst reports. Zacks Investment Research upgraded Vical from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Vical in a report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $7.50.

Shares of Vical (NASDAQ:VICL) traded up $0.01 during mid-day trading on Thursday, reaching $1.84. The company had a trading volume of 48,200 shares, compared to its average volume of 112,400. Vical has a 1 year low of $1.66 and a 1 year high of $3.70. The firm has a market cap of $22.88, a PE ratio of -1.72 and a beta of 1.84.

Vical (NASDAQ:VICL) last released its earnings results on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $3.24 million for the quarter, compared to analyst estimates of $3.60 million. Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. equities research analysts forecast that Vical will post -1 EPS for the current year.

In other news, Director Robert C. Merton purchased 85,700 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $1.75 per share, with a total value of $149,975.00. Following the purchase, the director now directly owns 95,451 shares of the company’s stock, valued at $167,039.25. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.88% of the stock is owned by insiders.

WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at

About Vical

Insider Buying and Selling by Quarter for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply